The high affinity receptor for immunoglobulin E: Lessons from structural analysis;Le récepteur de forte affinité pour l'igE: Leçons d'une analyse structurale

Medecine/Sciences

Volumn 19, Issue 1, 2003, Pages 63-69

  Blank, Ulrich ^a   Guérin Marchand, Claudine ^a   Kinet, Jean Pierre ^b  

^a INSTITUT PASTEUR   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; FC RECEPTOR; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; LIGAND;

ALLERGIC ASTHMA; ALLERGIC REACTION; ALLERGIC RHINITIS; BASOPHIL; CELL ACTIVATION; DRUG EFFICACY; HUMAN; LIGAND BINDING; MAST CELL; MEDIATOR RELEASE; PREVALENCE; RECEPTOR AFFINITY; REVIEW;

EID: 0346665919     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200319163     Document Type: Review

References (40)

1. Daëron M. Fc receptor biology. Annu Rev Immunol 1997; 15: 203-34.
2. Sutton BJ, Gould HJ. The human IgE network. Nature 1993; 366: 421-8.
3. Kinet JP. The high-affinity IgE receptor (FcERI): from physiology to pathology. Annu Rev Immunol 1999; 17: 931-72.
4. Kinet JP. Atopic allergy and other hypersensitivities. Curr Opin Immunol 1999; 11: 603-5.
5. Hagan P, Blumenthal D, Dunn AJ, Simpson B, Wilkins HA. Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature 1991; 349: 243-5.
6. Gounni AS, Lamkhioued B, Ochiai K, et al. High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 1994; 367: 183-6.
7. Jankovic D, Kullberg MC, Dombrowicz D, et al. FcERI-deficient mice infected with Schistosoma mansoni mount normal Th2-type responses while displaying enhanced liver pathology. J Immunol 1997; 159: 1868-75.
8. Blank U, Ra C, Miller L, White K, Metzger H, Kinet, JP. Complete structure and expression in transfected cells of high affinity IgE receptor. Nature 1989; 337: 187-9.
9. Garman, SC, Wurzburg BA, Tarchevskaya SS, Kinet JP, Jardetzky TS. Structure of the Fc fragment of human IgE bound to its high-affinity receptor FcERIa. Nature 2000; 406: 259-66.
10. Lin S, Cicala C, Scharenberg AM, Kinet JP. The FcERIb subunit functions as an amplifier of FcERIg-mediated cell activation signals. Cell 1996; 85: 985-95.
11. Donnadieu E, Jouvin MH, Kinet JP. A second amplifier function for the allergy-associated FcERI-b subunit. Immunity 2000; 12: 515-23.
12. Dombrowicz D, Lin S, Flamand V, Brini AT, Koller BH, Kinet JP. Allergy-associated FcRb is a molecular amplifier of IgE-and IgG-mediated in vivo responses. Immunity 1998; 8: 517-29.
13. Nissim A, Jouvin MH, Eshhar Z. Mapping of the high affinity Fce receptor binding site to the third constant region domain of IgE. EMBO J 1991; 10: 101-7.
14. Presto LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151: 2623-32.
15. Henry AJ, Cook JP, McDonnell JM, et al. Participation of the N-terminal region of CE3 in the binding of human IgE to its high-affinity receptor FcERI. Biochemistry 1997; 36: 15568-78.
16. Hakimi J, Seals C, Kondas JA, Danho W, Kochan J. The a subunit of the human IgE receptor is sufficient for high affinity IgE binding. J Biol Chem 1990; 265: 22079-81.
17. Blank U, Ra CS, Kinet JP. Characterization of truncated a chain products from human, rat, and mouse high affinity receptor for immunoglobulin E. J Biol Chem 1991; 266: 2639-46.
18. Letourneur O, Sechi S, Willette-Brown J, Robertson MW, Kinet JP. Glycosylation of human truncated FcERI a chain is necessary for efficient folding in the endoplasmic reticulum. J Biol Chem 1995; 270: 8249-56.
19. Cook JP, Henry AJ, McDonnell JM, Owens RJ, Sutton BJ, Gould HJ. Identification of contact residues in the IgE binding site of human FcERIa. Biochemistry 1997; 36: 15579-88.
20. Garman SC, Kinet JP, Jardetzky TS. Crystal structure of the human high-affinity IgE receptor. Cell 1998; 7: 951-61.
21. Mendoza G, Metzger H. Distribution and valency of receptor for IgE on rodent mast cells and related tumour cells. Nature 1976; 264: 548-50.
22. Sechi S, Roller PP, Willette-Brown J, Kinet JP. A conformational rearrangement upon binding of IgE to its high affinity receptor. J Biol Chem 1996; 271: 19256-63.
23. Wurzburg BA, Garman SC, Jardetzky TS. Structure of the human IgE-Fc CE3-C e-4 reveals conformational flexibility in the antibody effector domains. Immunity 2000; 13: 375-85.
24. Maxwell KF, Powell MS, Hulett MD, Barton PA, McKenzie J, Hogarth PM. Crystal structure of the human leukocyte Fc receptor, FcγRIIa. Nat Struct Biol 1999; 6: 437-42.
25. Sondermann P, Huber R, Jacob U. Crystal structure of the soluble form of the human FcγRIIb: a new member of the immunoglobulin superfamily at 1.7 Å resolution. EMBO J 1999; 18: 1095-103.
26. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-Å crystal structure of the human IgGI Fc fragment-FcγRIII complex. Nature 2000; 406: 267-73.
27. Radaev S, Motyka S, Fridman WH., Sautes-Fridman C, Sun PD. The structure of a human type III Fcg receptor in complex with Fc. J Biol Chem 2001; 276: 16469-77.
28. Ring J, Kramer U, Schafer T, Behrendt H. Why are allergies increasing? Curr Opin Immunol 2001; 13: 701-8.
29. Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995; 107: 308-12.
30. Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000; 18: 157-62.
31. Boulet P, Chapman KR, Cote J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155: 1835-40.
32. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155: 1828-34.
33. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999; 341: 1966-73.
34. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254-61.
35. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184-90.
36. Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100: 110-21.
37. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106: 253-9.
38. Fahy JV, Cockcroft DW, Boulet LP, et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 1999; 160: 1023-7.
39. Borkowski TA, Jouvin MH, Lin SY, Kinet JP. Minimal requirements for IgE-mediated regulation of surface Fc epsilon RI. J Immunol 2001; 167: 1290-6.
40. Saini SS, MacGlashan DW, Togias A, Adelman DC, Lichtenstein LM, Bochner BS. Down-regulation of human basophil IgE and FcERI a surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 1999; 162: 5624-30.